283153-64-0

Upstream product

• 67-56-1 methanol 
• 23359-08-2 4-formylcinnamic acid 
• 115974-97-5 methyl (E)-4-carboxyl cinnamate 
• 619-66-9 4-Carboxybenzaldehyde 
• 7560-50-1 methyl (2E)-3-(4-formylphenyl)acrylate 
• 141286-90-0 methyl (E)-3-(4-(hydroxymethyl)phenyl)acrylate 

Downstream Products

• 56703-34-5 3-[4-(hydroxymethyl)phenyl]propanoic acid 
• 1426441-01-1 methyl 3-(4-((benzyl(5-hydroxypentyl)carbamoyloxy)methyl)phenyl)propanoate 
• 1426441-02-2 methyl 3-(4-((benzyl(5-O-(tetrahydropyranyloxy)pentyl)carbamoyloxy)methyl)phenyl)propanoate 
• 1018674-58-2 cyclopentyl 4-(4-{3-[(1-isobutoxyethoxy)amino]-3-oxopropyl}benzyl)piperazine-2-carboxylate 
• 71924-53-3 methyl 3-(4-formyl-phenyl)propanoate 

Relevant academic research and scientific papers

Reduction of Electron-Deficient Alkenes Enabled by a Photoinduced Hydrogen Atom Transfer

Direct hydrogen atom transfer from a photoredox-generated Hantzsch ester radical cation to electron-deficient alkenes has enabled the development of an efficient formal hydrogenation under mild, operationally simple conditions. The HAT-driven mechanism is supported by experimental and computational studies. The reaction is applied to a variety of cinnamate derivatives and related structures, irrespective of the presence of electron-donating or electron-withdrawing substituents in the aromatic ring and with good functional group compatibility. (Figure presented.).

Acylsulfonamide safety-catch linker: Promise and limitations for solid-phase oligosaccharide synthesis

Safety-catch linkers are useful for solid-phase oligosaccharide synthesis as they are orthogonal to many common protective groups. A new acylsulfonamide safety-catch linker was designed, synthesized and employed during glycosylations using an automated carbohydrate synthesizer. The analysis of the cleavage products revealed shortcomings for oligosaccharide synthesis.

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

Cinnamamide derivatives and drug compositions containing the same

The invention relates to cinnamamide derivatives having the following formula wherein R1represents a hydroxyl group, a C1-6-alkoxy group, an arylalkoxy group or a substituted or unsubstituted amino group; R2and R3are same or different, each of which represents a hydrogen atom, a halogen atom or a C1-4-alkyl group; R4represents a hydrogen atom or a C1-6-alkyl group; R5represents a hydrogen atom, a C1-6-alkyl group or an aryl group; R6represents a hydrogen atom, a C1-6-alkyl group, a cyano group or a C1-6-alkoxy-carbonyl group; W represents an oxygen atom, a sulfur atom, an imino group, a methylene group, a hydroxymethylene group or a carbonyl group; X and Y are same or different, each of which represents an oxygen atom or a sulfur atom; m represents an integer of 0 to 2; n represents an integer of 1 to 3; and when m is 0, a group: —C(R2)(R3)—W— may represent a vinylene group; or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the above compound, in particular, an immunomodulatory agent and a prophylactic or therapeutic agent for nephrotic syndrome, circulatory disorders or respiratory diseases.